Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPEnews2025-06-16T14:40:26+00:00June 16th, 2025|Endpoints News|
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy datanews2025-06-13T14:18:50+00:00June 13th, 2025|Endpoints News|
ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for assetnews2025-06-12T14:31:06+00:00June 12th, 2025|Endpoints News|
Lilly pledges more than $650M to muscle health biotech; Cogent gets $50Mnews2025-06-11T14:32:45+00:00June 11th, 2025|Endpoints News|
Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issuesnews2025-06-10T14:49:27+00:00June 10th, 2025|Endpoints News|
Avidity to seek accelerated approval for FSHD drug; Axsome to run another trialnews2025-06-09T14:44:56+00:00June 9th, 2025|Endpoints News|
Kelun’s $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kidsnews2025-06-06T14:09:09+00:00June 6th, 2025|Endpoints News|
Cullinan’s deal for T cell engager from China; Kardigan buys late-stage heart drugnews2025-06-05T14:38:32+00:00June 5th, 2025|Endpoints News|
Vigil drug fails a Phase 2; Merus aims to raise $300Mnews2025-06-04T14:25:49+00:00June 4th, 2025|Endpoints News|
Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100Mnews2025-06-03T14:32:36+00:00June 3rd, 2025|Endpoints News|
